By increasing the immune response to cancer, targeting the YAP/TAZ pathway can potentially improve the efficacy of immunotherapy for H.C.C. It is important to note that while these preclinical studies provide promising results, further research is needed to fully understand the role of the YAP/TAZ pathway in the efficacy of immunotherapy for H.C.C. and to translate these findings into clinical practice. The gene discussed is YAP1; the disease is cancer.